Summary Despite widespread immunophenotyping in acute myeloid leukemia (AML), its immunophenotypic heterogeneity remains incompletely understood. Here, we applied state-of-the-art computational modeling to >50 million single cells from diagnostic bone marrow aspirates of 502 AML patients. Jointly modeling leukemic and...
T. Mocking, T. Reuvekamp, Lukas H. Haaksma et al.· iScience· 0 citations
SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML pati...
S. Eldfors, Sumit Rai, Vineet Sharma et al.· Leukemia· 0 citations
Background. Federated learning enables collaborative model development without transferring patient level data between institutions. However, translation into routine healthcare practice remains limited because deployment requires more than distributed model training. Federated infrastructures must operate within secur...
V. Nieminen, H. Schultze, S. Kukkurainen et al.· medRxiv· 0 citations
The results suggest that anti-TIM3 combined with decitabine engages a distinct mechanism of immune activation compared to anti-PD1 and anti-CTLA4, preferentially expanding NK-cell and CD4+ T-cell populations.
Jani Huuhtanen, S. Forstén, B. Ford et al.· Cancer immunology research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
